Skip to main content

Advertisement

Table 1 Baseline characteristics of patients identified from MarketScan

From: Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study

  RA patients (cases) Non-RA patients (controls) p valuea
N % N %
Total no. of patients 46,030 100 46,030 100
Age (years)      
Mean (SD) 56.61 (14.79)
Median (IQR) 57 (19)
18–29 1780 3.87 1780 3.87 1
30–39 4119 8.95 4119 8.95 1
40–49 8064 17.52 8064 17.52 1
50–59 12,735 27.67 12,735 27.67 1
60–69 10,428 22.65 10,428 22.65 1
≥70 8904 19.34 8904 19.34 1
Medical conditions
Cardiovascular disease 8330 18.10 6489 14.10 <0.0001
Chronic lung disease 2470 5.37 1604 3.48 <0.0001
Diabetes 5284 11.48 5475 11.89 0.0501
Cancer 9152 19.88 9362 20.34 0.0842
HIV/AIDS 44 0.10 47 0.10 0.753
Transplant 926 2.01 421 0.91 <0.0001
Renal dysfunction 474 1.03 425 0.92 0.1005
Neurological disorders 3465 7.53 183 0.40 <0.0001
Depression 2555 5.55 2542 5.52 0.8514
Medications at baseline
DMARDs 6413 13.93 642 1.39 <0.0001
Biologics 3276 7.12 104 0.23 <0.0001
Influenza vaccination 3500 7.60 4667 10.14 <0.0001
High-dose corticosteroidsb 10,056 21.85 4990 10.84 <0.0001
Low-dose corticosteroidsb 7903 17.17 1182 2.57 <0.0001
Antibiotics 28,847 62.67 24545 53.32 <0.0001
Statins 7408 16.09 7908 17.18 <0.0001
RA patients who had received no active medication
No DMARDs, biologics or corticosteroidsc 25,894 56.25 NA NA
Sex      
Male 15,230 33.09 15230 33.09 1
Female 30,800 66.91 30800 66.91 1
  1. Note: ap value of 1 indicates cases with matched controls; bPharmacy data were used to compute an average daily dose during a 6-month period prior to cohort entry. The average daily dose was unique for each individual course of corticosteroid therapy. ‘High dose’ referred to values that were greater than or equal to the average daily dose, while ‘low dose’ referred to values that were less than the average daily dose; cFrom 1 year prior to cohort entry until the end of the study; SD = standard deviation; IQR = interquartile range.